2023 | Nanologica

CEO Andreas Bhagwani is interviewed at Redeye after the release of the interim report Q2 2023

8 July, 2023

Intervju med vd Andreas Bhagwani gällande delårsrapporten för Q2 2023.

CEO Comment Q2 2023

7 July, 2023

ONE MILESTONE PASSED – NOW WE LOOK FORWARD During the quarter, we reached an important milestone when we were finally able to approve our product in chromatography – NLAB Saga® – and after that make the first delivery to a customer who will use it in their production of insulin. The fine-tuning of the production that we implemented at the beginning of the year were successful, and on May 3 we were able to approve

Interim Report Q2 2023 Nanologica AB (publ)

7 July, 2023

FINANCIAL SUMMARY Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388) Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK

Nanologica söker en Business Controller

29 June, 2023

Är du driven och motiveras av varierande arbetsuppgifter? Har du erfarenhet från producerande noterat bolag? Lockas du av en expansiv innovativ verksamhet? Då kan du vara den Business Controller som Nanologica söker! Vad får dig att trivas hos uppdragsgivaren Hos Nanologica får du jobba på ett bolag som vill förbättra för mänskligheten genom att bidra till att öka tillgängligheten till insulin och andra livsnödvändiga mediciner för patienter världen över. Bolaget är i början av en

In focus intervju med CEO Andreas Bhagwani på Redeye Growth Day 2023, 1 juni

2 June, 2023

Nanologica Delivers Silica to Latin-American Customer for Production of Insulin

1 June, 2023

As a result of Nanologica’s product in preparative chromatography, NLAB Saga®, reaching internal quality requirements, silica is now delivered to a customer in Latin America for production of diabetes drugs. The customer is a latin-american pharmaceutical manufacturer that manufactures, among other things, insulin and insulin analogues. This delivery refers to silica for the production of insulin. The delivery is made against a recent order with an order value of about TSEK 300. ”We have for

About us

Nanologica is a Swedish nanotechnology company, world-leading in the development of nanoporous silica particles for purification by chromatography. A proprietary production method enables the company to create supreme products by precisely controlling the shape, size, porosity, and surface properties of silica particles. Nanologica provides products of high-quality silica used in the purification of peptide drugs. These products can contribute to lower costs and higher production for pharmaceutical manufacturers, which increases the availability of cost-effective medicines and gives more people around the world access to vital treatment for diabetes and obesity. Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed on Nasdaq Stockholm Main Market.